Surgery Versus Perioperative Chemotherapy In Non Metastatic Muscle Invasive Bladder Carcinoma
Ali, S., El Sherbiny, M., Aly El- Wakil, M., Shaban, A. (2022). Surgery Versus Perioperative Chemotherapy In Non Metastatic Muscle Invasive Bladder Carcinoma. EKB Journal Management System, 3(1), 181-199. doi: 10.21608/ejmr.2022.221834
Sarah Hamdy Ali; Mamdouh El Sherbiny; Mohamed Aly El- Wakil; Ahmed Hassan Shaban. "Surgery Versus Perioperative Chemotherapy In Non Metastatic Muscle Invasive Bladder Carcinoma". EKB Journal Management System, 3, 1, 2022, 181-199. doi: 10.21608/ejmr.2022.221834
Ali, S., El Sherbiny, M., Aly El- Wakil, M., Shaban, A. (2022). 'Surgery Versus Perioperative Chemotherapy In Non Metastatic Muscle Invasive Bladder Carcinoma', EKB Journal Management System, 3(1), pp. 181-199. doi: 10.21608/ejmr.2022.221834
Ali, S., El Sherbiny, M., Aly El- Wakil, M., Shaban, A. Surgery Versus Perioperative Chemotherapy In Non Metastatic Muscle Invasive Bladder Carcinoma. EKB Journal Management System, 2022; 3(1): 181-199. doi: 10.21608/ejmr.2022.221834

Surgery Versus Perioperative Chemotherapy In Non Metastatic Muscle Invasive Bladder Carcinoma

Egyptian Journal of Medical Research
Article 14, Volume 3, Issue 1, January 2022, Page 181-199  XML PDF (608.98 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.221834
View on SCiNiTO View on SCiNiTO
Authors
Sarah Hamdy Ali1; Mamdouh El Sherbiny2; Mohamed Aly El- Wakil2; Ahmed Hassan Shabanorcid 2
1Oncology department, faculty of medicine, Beni seuf university, Egypt.
2Oncology department, faculty of medicine, Beni seuf university, Egypt.
Abstract
According to treatment  guidelines of urinary bladder carcinoma, using Neoadjuvent chemotherapy followed by radical cystectomy is the standard treatment which improve overall survival and progression free survival. This study is conducted to compare effect of (1) neoagjuvent  chemotherapy  followed by radical cystectomy with (2) radical cystectomy followed by adjuvant chemotherapy, (3) Radical cystectomy only on OS and PFS. Patients and methods: This a retrospective study of all patients with urinary bladder cancer attended  out patients at oncology , Beni seuf university hospital at period of 2013 to 2017 with follow up for 5 year.Results:  In our study mean progression free survival was 24.6 months, longest time was among the patients underwent  radical cystectomy followed by adjuvant chemotherapy with 27.8 months then neoadjuvant arm with 20.8 months then radical cystectomy only with 18.1 months with statistically significant difference between the three arms regarding the time spent till the occurrence of relapse (P-value<0.001).Mean over all survival was 27.1 months, the longest survival was among the patients underwent(1) radical cystectomy then adjuvant chemotherapy 28.1 months follow by patients who received(2) neoadjuvant with 23.1 months then(3) radical cystectomy with 20.7 months, there was a statistically significant difference between the three arms regarding the survival (P-value=0.003). Conclusion: Radical cystectomy followed by adjuvant treatment has the longest OS with 28.1 months and longest PFS with 27.8 months with statistical significant p value for OS 0.003* and for PFS <0.001**  .
Keywords
Neoadjuvant; adjuvant; Radical cystectomy; PFS; OS
References
  1.  Stein JP, LieskovskyG CoteR Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long term resultsin 1054 patients. J ClinOncol. (2001) 19:666–75. doi: 10.1200/JCO.2001.19.3.666
  2. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer B. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol. (2006) 176D2:486–92. discussion 491–2. doi: 10.1016/j.juro.2006.03.038
  3. AvellinoG J, Bose S,  Wang D S (2016). "Diagnosis and Management of Hematuria". Surgical Clinics of North America. . 96 (3): 503–515. doi:10.1016/j.suc.2016.02.007. ISSN 0039-6109. PMID 27261791.
  4. Burger  M, Catto  J W, Dalbagni  G,  et al., (2013). Epidemiology and risk factors of urothelial bladder cancer.  Eur Urol. 2013; 63(2):234-241.
  5. Vashistha V, Quinn DI, Dorff TB, Daneshmand S.(2014).Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. Dec 2014.
  6.  Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED.(2003). Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. Aug 2003.
  7. Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Nilsson S, Malmström PU; Nordic Urothelial Cancer Group.(2004). Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Mar 2004.
  8. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. (2005).Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Aug 2005.
  9. Vale CL Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta analysis collaboration. Eur Urol. (2005) 48:202–5, discussion 205-206. doi: 10.1016/j.eururo.2005.04.006
  10. Paz-Ares L, Solsona E, Esteban E, Saez A, Gonzalez-Larriba J, Anton A, et al. On behalf of the SOGUG and GUO-AEU groups Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the SOGUG (Spanish Oncology Genito-Urinary Group) 99/01 study. J Clin Oncol. (2010) 28(Suppl. 18):LBA4518. doi: 10.1200/jco.2010.28.18_suppl.lba4518
  11. Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N1M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. (2015) 16:76–86. doi: 10.1016/S1470-2045(14)71160-X
  12. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. (2014) 66:42–54. doi: 10.1016/j.eururo.2013.08.033
  13. Wosnitzer MS, Hruby GW, Murphy AM, Barlow LJ, Cordon-Cardo C, Mansukhani M, et al. A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer. Cancer (2012) 118:358–64. doi: 10.1002/cncr.26278
  14. Hyung Suk Kim,1 Chang Wook Jeong,2 Cheol Kwak,2 Hyeon Hoe Kim,2 and Ja Hyeon Ku2. Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials 2017 Sep 18. doi: 10.18632/oncotarget.20979
  15. Do Kyung Kim,1 Joo Yong Lee,2 Jae Hung Jung,3 Yoon Soo Hah,1 and Kang Su Cho1.Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials 2019 Jan 31. doi: 10.4111/icu.2019.60.2.64
  16. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. (2001) 19:4005–13. doi: 10.1200/JCO.2001.19.20.4005
  17. Matthew S. wosnitzer MD, Gregory W. Hruby BA, Alana M. MurphyMD,lamont J. barlow MD, carlos cordon-cardo MD,phD, Mahesh Mansukhani MD, Daniel P. petrylak MD,  Mitchell C. Benson MD, james M. Mckiernan MD.29 june 2011. A comparison of the out comes of neoadjuvent and adjuvant chemotherapy for clinical T2-T4a N0- N2 M0 bladder cancer.
  18. Matsubara N, Mukai H, Naito Y, Nezu M, Itoh K. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer. Asia Pac J Clin Oncol. (2013) 9:310–7. doi: 10.1111/ajco.12017
  19. Sonpavde G, Nelson RA, Trinh QD, Agarwal N, Nix J, Kardos S, et al. Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB). J Clin Oncol. 34(15_Suppl):4524. doi: 10.1200/JCO.2016.34.15_suppl.4524
  20. van de Putte EEF, Mertens LS, Meijer RP, van der Heijden MS, Bex A, van der Poel HG, et al. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin. World J Urol. (2016) 34:157–62. doi: 10.1007/s00345-015-1636-y
  21. Abbas Rezaianzadeh, Abolfazl Mohammadbeigi, Jafar Mobaleghi, and Narges Mohammadsalehi3,2012.Survival analysis of patients with bladder cancer, life table approach, Jul 2012.
  22. Nobuaki Matsubara  Hirofumi Mukai Yoichi Naito Masahiko Nezu Kuniaki Itoh.Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle‐invasive bladder cancer. 06 November 2012 https://doi.org/10.1111/ajco.12017
  23. Gabriella Del Bene1, Fabio Calabrò1, Diana Giannarelli2, Elizabeth R. Plimack3, Lauren C. Harshman4, Evan Y. Yu5, Simon J. Crabb6, Sumanta Kumar Pal7, Ajjai S. Alva8, Thomas Powles9, Ugo De Giorgi10, Neeraj Agarwal11, Aristotelis Bamias12, Sylvain Ladoire13, Andrea Necchi14, Ulka N. Vaishampayan15, Günter Niegisch16, Joaquim Bellmunt4, Jack Baniel17, Matthew D. Galsky18 and Cora N. Sternberg1* on behalf of the RISC Investigators. Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. Oncol., 19 November 2018 | https://doi.org/10.3389/fonc.2018.00463
 

 

Statistics
Article View: 223
PDF Download: 157